PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces the first close of its ...

Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long ...

The "Ocular Melanoma - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.The report delivers an in-depth understanding of ocular melanoma, historical and ...

NT-501 (revakinagene taroretcel) is an encapsulated cell therapy designed to continuously release therapeutic ciliary neurotrophic factor to the back of the eye. The ocular implant received ...

This article was accepted for publication via eLife's original publishing model. eLife publishes the authors' accepted manuscript as a PDF only version before the full Version of Record is ready for ...